GIM
XENE icon

Granahan Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

Granahan Investment Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.08M Buy
104,478
+11,700
+13% +$539K 0.29% 89
2025
Q4 		$4.16M Buy
92,778
+5,308
+6% +$223K 0.18% 120
2025
Q3 		$3.51M Sell
87,470
-152,568
-64% -$5.37M 0.14% 115
2025
Q2 		$7.51M Buy
240,038
+56,230
+31% +$1.83M 0.31% 81
2025
Q1 		$6.17M Buy
183,808
+1,475
+0.8% +$56K 0.31% 86
2024
Q4 		$7.15M Sell
182,333
-18,544
-9% -$767K 0.3% 86
2024
Q3 		$7.91M Sell
200,877
-25,289
-11% -$1.02M 0.31% 97
2024
Q2 		$8.82M Sell
226,166
-17,914
-7% -$716K 0.35% 87
2024
Q1 		$10.5M Sell
244,080
-58,501
-19% -$2.69M 0.37% 81
2023
Q4 		$13.9M Buy
302,581
+66,291
+28% +$2.34M 0.46% 70
2023
Q3 		$8.07M Sell
236,290
-463
-0.2% -$17.3K 0.29% 100
2023
Q2 		$9.11M Sell
236,753
-39,259
-14% -$1.56M 0.28% 95
2023
Q1 		$9.88M Sell
276,012
-48,238
-15% -$1.78M 0.3% 91
2022
Q4 		$12.8M Buy
324,250
+24,395
+8% +$888K 0.39% 72
2022
Q3 		$10.8M Buy
299,855
+15,083
+5% +$542K 0.35% 86
2022
Q2 		$8.66M Buy
284,772
+22,067
+8% +$667K 0.3% 89
2022
Q1 		$8.03M Buy
262,705
+45,404
+21% +$1.36M 0.2% 105
2021
Q4 		$6.79M Buy
217,301
+133,447
+159% +$3.99M 0.14% 134
2021
Q3 		$1.28M Buy
83,854
+605
+0.7% +$10.5K 0.02% 184
2021
Q2 		$1.55M Buy
83,249
+161
+0.2% +$2.97K 0.03% 182
2021
Q1 		$1.49M Sell
83,088
-70,233
-46% -$1.19M 0.03% 177
2020
Q4 		$2.36M Sell
153,321
-5,383
-3% -$63K 0.05% 171
2020
Q3 		$1.76M Buy
158,704
+47,705
+43% +$561K 0.06% 160
2020
Q2 		$1.39M Hold
110,999
– – 0.05% 161
2020
Q1 		$1.26M Buy
110,999
+4,160
+4% +$59.2K 0.07% 156
2019
Q4 		$1.4M Buy
106,839
+380
+0.4% +$4K 0.06% 150
2019
Q3 		$959K Buy
106,459
+8,200
+8% +$77.5K 0.05% 156
2019
Q2 		$969K Sell
98,259
-10,420
-10% -$99.7K 0.05% 164
2019
Q1 		$1.1M Buy
+108,679
New +$921K 0.06% 169

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Granahan Investment Management's XENE Position: Q1 2026 in Review

Granahan Investment Management increased its Xenon Pharmaceuticals (XENE) stake by 13% in Q1 2026, buying an estimated $539K and bringing the position to 104,478 shares worth $6.08M. The position accounts for 0.29% of the portfolio, ranked #89.

Granahan Investment Management first reported a position in XENE in Q1 2019 and has held it in 29 quarters since. The position peaked at $13.9M in Q4 2023. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Granahan Investment Management held 104,478 shares of Xenon Pharmaceuticals worth $6.08M as of Q1 2026.
  • Granahan Investment Management bought 11,700 Xenon Pharmaceuticals shares in Q1 2026, an estimated $539K.
  • Xenon Pharmaceuticals made up 0.29% of Granahan Investment Management's portfolio in Q1 2026, its #89 holding.
  • Granahan Investment Management first reported a position in Xenon Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Granahan Investment Management's Xenon Pharmaceuticals position peaked at $13.9M in Q4 2023.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.